医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

BRUKINSA

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: BeiGene Receives BRUKINSA CLL zanubrutinib

2022年11月17日

BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers

バイオテクノロジーヘルスケア医療機器腫瘍学　 TimeLine: As a Treatment for Rare Blood Cancers BeiGene Announces Brazil Approvals for BRUKINSA

2022年11月10日

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Receives BRUKINSA European Commission Approval for zanubrutinib

2022年11月02日

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Receives Positive CHMP BRUKINSA Opinion for zanubrutinib

2022年09月19日

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces BRUKINSA Markets zanubrutinib

2022年06月13日

IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BRUKINSA Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia IRC Determines zanubrutinib

2022年04月11日

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BRUKINSA for the Treatment of Waldenström s Macroglobulinemia zanubrutinib

2022年03月15日

$BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma$

BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces Health Canada Approval for BRUKINSA in Relapsed or Refractory Marginal Zone Lymphoma zanubrutinib

2022年03月03日

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

ヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces BRUKINSA FDA Acceptance of Supplemental New Drug in Chronic Lymphocytic Leukemia zanubrutinib

2022年02月22日

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma zanubrutinib

2022年02月22日